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Potentiated therapeutic angiogenesis by primed 
human mesenchymal stem cells in a mouse model 
of hindlimb ischemia
Ischemia is a common and fatal human disorder 
associated with decreased blood supply to certain 
organs or tissues. Ischemia is caused by patho-
logical changes in the vascular system, such 
as constriction and obstruction. For example, 
peripheral arterial obstructive disease, which is 
mainly primed by atherosclerosis, causes lower-
limb ischemia and usually results in amputation. 
The goal of ‘therapeutic angiogenesis’ is to treat 
ischemic disorders, such as limb ischemia and 
myocardial infarction, by stimulating new blood 
vessel growth from pre-existing vessels [1–3].
Human bone marrow-derived mesenchymal 
stem cells (hMSCs) are an ideal cell source for 
autologous cell-based therapy owing to their 
self-renewal capacity in vitro, high plasticity 
and low immunogenicity. In addition, hMSCs 
could be very useful for clinical application since 
they inhibit the immunological responses and 
do not need a major histocompatibility match 
for allogeneic transplantation [4–6]. Transplant-
ing MSCs induces neovascularization and 
improves blood flow to ischemic limbs in ani-
mal models of hindlimb ischemia [7–9]. It has 
also been demonstrated that growth factors and 
cytokines released by MSCs promote in vitro and 
in vivo arteriogenesis in ischemic tissue through 
paracrine mechanisms [10].
VEGF was originally shown to play an 
essential role in promoting angiogenesis dur-
ing develop ment [11–13]. In addition, VEGF is 
one of the most important proangiogenic fac-
tors involved in therapeutic angiogenesis during 
and after ischemia [1,10]. HGF is another potent 
pro angiogenic factor that induces migration 
and proliferation and inhibits the apoptotic cell 
death of endothelial cells (ECs) [14].
Our previous studies demonstrated that 
hMSCs without genetic modification could be 
induced into Schwann cell-like cells that release 
higher amounts of VEGF and HGF when com-
pared with control hMSCs [15]. Moreover, these 
induced hMSCs rendered the tissue micro-
environment more favorable for tissue repair by 
secreting various growth factors that promote cell 
survival in a model of spinal cord injury [15]. In 
this study, we investigated whether these primed 
hMSCs could enhance therapeutic angio genesis 
to treat ischemic disease. We demonstrate that 
bone marrow-derived hMSCs primed to release 
high amounts of VEGF and HGF in vitro and 
transplanted into a mouse hindlimb ischemia 
model led to significant improvements in tis-
sue perfusion and limb salvage by enhancing 
therapeutic angiogenesis. Thus, the present 
study provides a novel approach to enhance the 
angiogenic potential of hMSCs without genetic 
modification to treat ischemic diseases.
Materials & methods
 Culture of hMSCs
Adult hMSCs purchased from Cambrex (MD, 
USA) were cultured in DMEM-low glucose 
(HyClone, UT, USA) with 10% fetal bovine 
serum (Gibco-BRL, CA, USA) and 1% penicil-
lin–streptomycin (Gibco-BRL). Cells (number 
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 Priming of hMSCs
hMSCs were primed as previously described 
by our group [15]. Briefly, hMSCs were treated 
with 1 mM b-mercaptoethanol (Sigma-Aldrich, 
MO, USA) for 24 h and 0.28 µg/ml all-trans-
retinoic acid (Sigma-Aldrich) for 3 days. Then, 
cells were treated with a cocktail containing 
10 µM forskolin (Sigma-Aldrich), 10 ng/ml 
recombinant human bFGF (PeproTech, NJ, 
USA), 5 ng/ml recombinant human PDGF-AA 
(PeproTech) and 200 ng/ml recombinant human 
heregulin-b1 (R&D Systems, ON, Canada) for 
8 days.
 Reverse transcription PCR
The RNA extraction by the TRIzol Reagent 
(Invitrogen, CA, USA) was followed by DNase 
treatment and then reverse transcription to 
cDNA using a M-MLV reverse transcriptase 
(Invitrogen). Next, the PCR reaction (50 µl) 
containing 200 nM dNTPs, 100 pM of each 
primer pair and 0.5 U of Taq DNA polymer-
ase (Takara Bio, Japan) was performed using an 
aliquot of cDNA (200 ng) as a template. The 
primer probe sets used for the PCR reactions are 
described in Table 1. The PCR products were elec-
trophoresed on 2% agarose gel, and each tran-
script abundance was measured and normalized 
based on GAPDH transcript level. 
 ELISA
After being rinsed four times with phosphate-
buffered saline (PBS), control hMSCs or primed 
hMSCs (4000 cells/cm2) were incubated with 
serum-free Neurobasal Media (Gibco-BRL) for 
18 h. Then, the conditioned media from control 
or primed hMSCs were centrifuged at 1500 × g 
for 5 min to remove cell debris, and analyzed 
by the ELISA kit for human VEGF/HGF (Ray-
Biotech, GA, USA) based on the manufacturer’s 
instructions.
 Mouse model of hindlimb ischemia
All procedures involving animals were approved 
by the Experimental Animal Committee of 
Clinical Research Institute, Seoul National 
University Hospital (Republic of Korea). All 
animals received humane care in compli-
ance with the ‘Guide for the Care and Use of 
Laboratory Animals’ published by the NIH [101].
Six-week-old (20–22 g) BALB/c nude mice 
(Orientbio, Sungnam, Republic of Korea [102]) 
were anesthetized by an intraperitoneal injec-
tion of ketamine (50 mg/kg) and xylazine 
(20 mg/kg) (Bayer Korea, Korea). By using 
a skin incision with 6-0 silk (Ethicon, NJ, 
USA), the femoral artery and its branches were 
tied. Additionally, the external iliac artery and 
all of the above arteries were tied. We ampu-
tated the femoral artery from its proximal 
site as a branch of the external iliac artery to 
the terminal point into which it divides into 
two parts, which are called the saphenous 
and popliteal arteries [16]. For the sampling of 
the lower calf muscles in the ischemic limb, 
the mice were sacrif iced by exposing them 
to an overdose of anesthetics at day 14 after 
hindlimb ischemia.
 hMSC transplantation into hindlimb 
ischemia
Mice with ischemic limbs were randomly allo-
cated into three groups that received the follow-
ing injections: vehicle alone; nonprimed con-
trol hMSCs; or primed hMSCs. Immediately 
after surgery, mice were injected intramuscu-
larly using 27-gauge tuberculin syringes at two 
sites within the gracilis muscle in the medial 
thigh with hMSCs (50,000 cells/mouse) sus-
pended in 60 µl of vehicle or vehicle alone. 
We have found that intramuscular injection 
of total cell numbers corresponding to 50,000 
cells is optimal for 6-week-old (20–22 g) 
BALB/c nude mice. This was previously opti-
mized by our group in a similar experimental 
model [17].
Table 1. PCR primer pairs.
Gene Accession 
number





















452 58 24 [45]
F: Forward; R: Reverse; temp.: Temperature.
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 Laser Doppler imaging ana lysis
In order to measure the serial noninvasive physi-
ological evaluation of neovascularization, a laser 
Doppler perfusion imager (Moor Instruments, 
UK) was used for mapping tissue blood flow by 
the shift in the laser light frequency. At days 0, 
7 and 14 after treatment, mice were observed 
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Figure 1. Priming of human mesenchymal stem cells and cell transplantation into a mouse model of hindlimb ischemia. 
(A) Schematic illustration of the protocol used for the priming of hMSCs and cell transplantation into a mouse model of hindlimb 
ischemia. (B) Bright-field images of control and primed hMSCs. After priming, hMSCs showed an elongated bipolar shape. Scale bar: 
200 µm. (C) Reverse transcription PCR analysis of hVEGF and hHGF mRNA levels in control hMSCs and primed hMSCs. (D) Quantitation 
of VEGF and HGF PCR products. The mRNA level of each gene was quantitated by densitometry and normalized to the corresponding 
GAPDH mRNA level. Each bars represent mean ± the standard error of the mean of three independent experiments. p-values were 
obtained by Student’s t-test. (E) ELISA ana lysis for hVEGF and hHGF released by control hMSCs and primed hMSCs. Each bar represents 
mean ± the standard error of the mean of three independent experiments. p-values were obtained by Student’s t-test. 
b-ME: b-mercaptoethanol; All-trans-RA: All-trans-retinoic acid; D: Day; FBS/DMEM: Fetal bovine serum/DMEM; hHGF: Human HGF; 
hMSC: Human mesenchymal stem cell; hVEGF: Human VEGF.
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in hindlimbs. To qualify blood flow at the site 
from the knee joint to the toe, the digital color-
coded images were utilized after laser Doppler 
perfusion imager scanning, and mean values of 
perfusion were also evaluated. In these digital 
color-coded images, red is shown in areas with 
maximum perfusion values, medium perfusion 
values are indicated in yellow and blue represents 
areas with lowest perfusion values.
We measured hindlimb perfusion as the ratio 
of ischemic to nonischemic in order to avoid data 
variation on account of ambient condition.
 Immunofluorescence
Tissue sections from the lower calf muscles 
of ischemic and healthy limbs were harvested 
14 days after cell transplantation and embed-
ded in paraffin (Tissue-Tek; Sakura, CA, USA). 
Sections were deparaffinized and then subjected 
to antigen retrieval with citrate buffer (Dako, 
Denmark). Blocking was performed by incubat-
ing sections for 1 h with 5% normal goat serum in 
PBS. Staining of capillaries in the ischemic regions 
were achieved by overnight incubation at 4°C 
with goat polyclonal anti-PECAM-1 (Santa Cruz 
Biotechnology, CA, USA) at 1:100 final dilution 
in blocking buffer. After this, the sections were 
washed three times with PBS and then incubated 
with donkey anti-goat conjugated with Alexa 
Fluor 555 at 1:500 final dilution (Invitrogen). 
Transplanted human cells in the sections were 
identified by incubating with mouse monoclonal 
anti-human nuclei (1:500; Chemicon, CA, USA).
To examine the expression of human-specific 
VEGF and HGF in ischemic tissues, sections were 
incubated with rabbit monoclonal anti-human 
VEGF (1:50; Abcam, UK) and mouse monoclo-
nal anti-human HGF (1:50; R&D Systems). After 
washing three-times, sections were incubated with 
goat anti-mouse conjugated with Alexa Fluor 546 
(1:200; Invitrogen) or goat antirabbit conjugated 
with Alexa Fluor 488 (1:200; Invitrogen). Cells 
were counterstained with 4’,6-diamidino-2-phe-
nylindole (Santa Cruz Biotechnology) for nuclear 
staining. The images were captured using a laser-
scanning confocal microscope, Fluoview FV300 
(Olympus, Japan).
 Statistical ana lysis
Quantitative data are presented as the mean ± the 
standard error of the mean. The unpaired t-test 
was used to compare continuous variables. One-
way ana lysis of variance with Tukey post hoc 
ana lysis was utilized to compare ≥3 groups with 
regard to continuous response variables. All sta-
tistical analyses were performed with GraphPad 
Prism 5.0 software (GraphPad Software Inc., CA, 
USA). p-values <0.05 were considered significant.
Results
 Characterization of primed hMSCs
Our previous study has reported that induction 
of hMSCs into Schwann cell-like cells promotes 
secretion of various growth factors. Interest-
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Figure 2. Primed human mesenchymal stem cell transplantation enhances 
blood flow in ischemic hindlimbs. (A) Serial ana lysis of LDPI performed at 0, 7 
and 14 days after transplantation. Primed hMSC transplantation resulted in greater 
limb blood perfusion in the ischemic limbs of mice than vehicle injection or hMSC 
transplantation. (B) The blood perfusion ratio of ischemic limbs measured by LDPI 
at 0, 7 and 14 days after transplantation. The ratio of ischemic to normal limb 
blood perfusion was significantly increased in primed hMSC-transplanted mice 
compared with the vehicle- and hMSC-transplanted mice at 7 and 14 days after 
transplantation. The bars represent mean ± the standard error of the mean 
(n = 4–5 mice per group). Please see color figure at www.futuremedicine.com/doi/
pdf/10.2217/rme.13.17. 
*p < 0.05; **p < 0.001 versus vehicle injection group; ***p < 0.05 versus hMSC-
transplanted group. The significance was determined by one-way ana lysis of 
variance with Tukey post hoc analysis. 
hMSC: Human mesenchymal stem cell; LDPI: Laser Doppler perfusion imaging.
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and HGF [15]. These factors directly functioned 
as neurotrophic factors for both Neuro2A cells 
in vitro and spinal nerves in an organotypic spinal 
cord slice culture [15]. Since VEGF and HGF are 
also angiogenic factors, we sought to determine 
whether the transplantation of these primed cells 
has therapeutic effects for ischemic diseases using 
the mouse hindlimb ischemia model, as described 
in Figure 1a. Here, we used nude mice to avoid 
immunological complications from xenogenic cell 
transplantation [18].
Cells used in this study were defined as 
MSCs based on conventions set forth by the 
International Society for Cellular Therapy based 
on fact that they express CD105, CD73 and 
CD90, and differentiate to osteoblasts, adipo-
cytes and chondroblasts in vitro [19]. Nonprimed 
control hMSCs exhibited a flattened symmetrical 
fibroblast-like morphology (Figure 1b). However, 
after induction into Schwann cell-like cells, 
primed hMSCs showed an elongated bi polar 
Schwann cell-like shape (Figure 1b). After prim-
ing, VEGF and HGF mRNA levels in primed 
hMSCs significantly increased by up to 3.4-fold 
(p < 0.05) and 2.3-fold (p < 0.05) compared 
with control hMSCs, respectively (Figure 1C & 1D). 
These increases were also noted at the protein 
level in the cell culture media by ELISA ana lysis, 
as previously described [15]. VEGF and HGF lev-
els were 3974.7 ± 213.5 and 493.7 ± 35.3 pg/ml, 
respectively, for primed hMSCs and 682.0 ± 18.5 
and 36.4 ± 1.2 pg/ml, respectively, for control 
hMSCs (Figure 1e). Taken together, this indicates 
that there was a significant induction of VEGF 
and HGF in primed hMSCs when compared 
with control hMSCs (p < 0.05).
 Blood perfusion in ischemic limbs 
& ischemic limb salvage is improved by 
primed hMSC transplantation
We investigated whether transplanting primed 
hMSCs had an effect on blood f low to the 
ischemic area of mice by Laser Doppler perfu-
sion imaging ana lysis (Figure 1a & 2a). Seven days 
after transplantation, the relative ratio of blood 
flow (ischemic limb to normal limb) was signifi-
cantly higher in primed hMSC-transplanted mice 
(18.59 ± 2.99%; p < 0.05) than in mice trans-
planted with nonprimed hMSCs (7.23 ± 0.61%) 
and vehicle-injected mice (7.62 ± 1.40%; 
Figure 2b). No difference in the relative ratio of 
blood flow was observed between hMSC-trans-
planted and the vehicle-injected groups. Fourteen 
days after transplantation, both hMSC-trans-
planted (15.80 ± 2.18%; p < 0.05) and primed 
hMSC-transplanted (24.22 ± 1.38%; p < 0.001) 
groups showed significant increases in the relative 
ratio of blood perfusion compared with the vehi-
cle group (4.92 ± 0.39%; Figure 2b). In addition, a 
significant difference in the relative ratio of blood 
flow was observed between control hMSC- and 
primed hMSC-transplanted groups (p < 0.05) 
(Figure 2b). Taken together, this indicated that 
blood perfusion in ischemic limbs was improved 
greatly in the primed hMSC-transplanted group 
compared with that in the vehicle- and control 
hMSC-transplanted group.
The ischemic limb salvage was also improved 
greatly by primed hMSC transplantation. Intra-
muscular transplantation of primed hMSCs 
reduced the rate of limb loss compared with 
that in the vehicle injection and control hMSC- 
transplantation groups (SupplemenTary Figure 1; 
see online www.futuremedicine.com/doi/
suppl/10.2217/rme.13.17). The mice receiving 
vehicle injection underwent limb loss (four of 
five) or severe limb necrosis (one of five). Despite 
the increased relative ratio of blood perfusion 
compared with the vehicle group 14 days after 
transplantation, all mice receiving control hMSC 
transplantation exhibited limb necrosis (four of 
four) but not limb loss. By contrast, four of five 
mice that received primed hMSC transplanta-
tion retained their limbs with minimal necrosis 
(SupplemenTary Figure 1).
 Primed hMSC transplantation 
increases angiogenesis in ischemic limbs
To examine whether transplantation of primed 
hMSCs promoted angiogenesis in ischemic limb 
tissues, we further analyzed mouse vasculature 
by immunohistochemical staining for PECAM-1 
after sacrificing mice 14 days after transplantation 
(Figure 3a). To measure capillary density, quantita-
tive ana lysis of PECAM-1 density was performed 
(Figure 3b). Then, the integrated optical density was 
normalized to the control hMSC-transplantation 
group, and expressed as the mean ± the standard 
error of the mean. A significant difference in the 
capillary density was observed between control 
hMSC- and primed hMSC-transplanted groups 
(p < 0.05) indicating that primed hMSC trans-
plantation significantly enhanced angiogenesis in 
ischemic limbs (Figure 3b).
 Transplanted hMSCs remain in 
ischemic areas
We investigated whether transplanted cells 
remained in ischemic tissues 14 days after 
transplantation (Figure 4). Immunofluorescent 
staining for human nuclei revealed that human 
nuclei-positive cells were present in both control 
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hMSC- and primed hMSC-transplanted limb 
tissues but not in vehicle-injected limb tissues 
(Figure 4a). Interestingly, a significant difference 
in the number of remaining human cells per 
area of 0.27 mm2 was observed between control 
hMSC- and primed hMSC-transplanted tis-
sues (p < 0.05) indicating that primed hMSC 
survived better in ischemic limbs (Figure 4b).
 Increases in VEGF & HGF in the 
transplanted hMSC
We next investigated whether human VEGF 
and HGF were increased in the ischemic 
tissues transplanted with primed hMSCs 
(Figure 5a & 5b). Immunohistochemical stain-
ing for human VEGF and HGF demonstrated 
significant levels of both factors in the group 
transplanted with primed hMSCs; whereas 
there was undetectable to low levels of these 
factors in the sham and mice transplanted 
with nonprimed hMSCs (Figure 5a & 5b). These 
results suggest that primed hMSCs survived 
after transplantation and secreted high lev-
els of human VEGF and HGF to enhance 
angiogenesis in the ischemic tissues.
Discussion
Our study demonstrates that hMSCs without 
genetic modification can be primed in vitro to 
secrete copious amounts of specific angiogenic 
growth factors that promote therapeutic angio-
genesis in vivo. Both mRNA and protein levels 
of VEGF and HGF increased significantly in 
primed hMSCs when compared with those in 
control hMSCs. Most importantly, primed 
cells survived 14 days after being transplanted 
in vivo and secreted high levels of human 
VEGF and HGF in the ischemic tissues. In 
this study, transplanting nonprimed hMSCs 
also induced capillary formation and improved 
blood flow to ischemic limbs, as previously 
reported [7–9]. However, transplanting primed 
hMSCs led to a significant improvement in tis-
sue perfusion and limb salvage by increasing 
capillary formation.
In our previous report, we observed con-
sistency in blood flow recovery of ischemic 
hindlimbs from day 14 to 21 after transplan-
tation [17]. Similarly, in this study, 14 days after 
transplantation, both hMSC-transplanted 
(p < 0.05) and primed hMSC-transplanted 
(p < 0.001) groups showed significant increases 
in the relative ratio of blood perfusion com-
pared with the vehicle group (Figure 2b). In 
addition, a significant difference in the relative 
ratio of blood flow was observed between con-
trol hMSC- and primed hMSC-transplanted 
groups (p < 0.05) (Figure 2b). Thus, the longer 
time period was not included in this study.
MSCs are multipotent and can differentiate 
into various mesodermal cells such as osteo-
blasts [20–22]. In addition, MSCs have the poten-
tial to transdifferentiate into vascular smooth 
muscle cells and pericytes [23]. However, it has 
been suggested that the paracrine properties of 
MSCs have a greater effect on tissue repair than 
transdifferentiation by modulating the tissue 
microenvironment [24]. Our previous study 








































Figure 3. Enhanced angiogenesis in ischemic limb tissues by primed human 
mesenchymal stem cell transplantation. (A) Representative confocal images of 
PECAM-1 immunofluorescence in control hMSC- and primed hMSC-transplanted 
ischemic hindlimbs 14 days after transplantation. Transplantation of primed hMSCs 
significantly induced the generation of new capillaries in the ischemic limbs 
compared with control hMSC transplantation. Scale bar: 50 µm. (B) Quantitative 
ana lysis of relative PECAM-1-positive capillary density in control hMSC- and primed 
hMSC-transplanted ischemic hindlimbs 14 days after transplantation. The bars 
represent the mean ± the standard error of the mean (n = 4 mice/group). The 
p-value was generated by the Student’s t-test. Please see color figure at  
www.futuremedicine.com/doi/pdf/10.2217/rme.13.17. 
hMSC: Human mesenchymal stem cell.
Regen. Med. (2013) 8(3)288 future science group
Therapeutic angiogenesis by primed human mesenchymal stem cells ReseaRch aRticle
by primed hMSCs directly facilitate axonal 
regeneration while, at the same time, protecting 
the resident cells at the site of tissue injury in 
an ex vivo model of spinal cord injury [15]. This 
study also suggests that the paracrine action of 
angiogenic factors secreted by primed hMSCs 
plays a greater role in therapeutic angiogenesis 
than transdifferentiation of these cells into ECs 
and/or direct participation in angiogenesis.
Angiogenesis and vasculogenesis are the 
major mechanisms involved in ischemic tissue 
neo vascularization [25]. Angiogenesis is the for-
mation of new blood vessels from pre-existing 
vessels, whereas vasculogenesis is the formation 
of new blood vessels when there are no pre-
existing vessels. Our results suggest that endo-
genous ECs begin sprouting to form capillar-
ies in response to VEGF and HGF secreted by 
primed hMSCs. However, it would be interest-
ing to examine whether primed hMSCs trans-
differentiate into endothelial precursor cells 
(EPCs) and/or ECs to form new blood vessels 
in response to local cues, although the prob-
ability is very low. Furthermore, the possibility 
that vasculogenesis also occurs by a mecha-
nism in which endogenous EPCs migrate and 
differentiate in response to angiogenic factors 
secreted by primed hMSCs to form new blood 
vessels cannot be excluded. Several studies 
have reported that stem cells can either directly 
enhance angiogenesis by inducing neovasculari-
zation [26] or indirectly enhance angiogenesis by 
secreting various angiogenic and antiapoptotic 
factors [10].
VEGF stimulates proliferation, migration 
and survival of ECs. It is also possible that 
VEGF secreted by primed cells can mobilize 
bone marrow-derived EPCs into neovasculari-
zation sites [27]. As EPCs can differentiate into 
ECs [28], it is likely that they can be incorpo-
rated into growing vessels and complement 
resident ECs to sprout new vessels [1]. How-
ever, the exact role of these cells in therapeu-
tic angiogenesis has not been clearly identi-
fied. Therefore, whether EPCs are recruited 
to ischemic areas by VEGF and other factors 
secreted from primed cells remains to be deter-
mined. Nevertheless, significant increases in 
capillary density were observed at the sites of 
primed cell transplantation. This suggests that 
the paracrine action of primed hMSCs plays an 
important role in therapeutic angiogenesis in 
the ischemic tissues.
The VEGF family comprises seven mem-
bers, including VEGF-A, VEGF-B, VEGF-C, 
VEGF-D, VEGF-E, VEGF-F and PGF [29]. 
Among the seven isoforms of VEGF-A, the 
primed cells secrete VEGF-A
165
, which is the 
most abundant and biologically active form 
[15,30–32]. hMSCs express the VEGF recep-
tors NP1 and NP2, which bind VEGF
165 
[33]. 















































Figure 4. Transplanted human mesenchymal stem cells survive in ischemic 
limb tissues. (A) Representative confocal images of immunostained human nuclei 
in the sham-, hMSC- and primed hMSC-transplanted ischemic hindlimbs 14 days 
after transplantation. Transplanted human cells were detected with Alexa 
Fluor 546-conjugated antibodies (red). The nuclei were visualized by DAPI staining 
(blue). Arrowheads indicate the immunostained HuNu. Scale bar: 20 µm. 
(B) Number of remaining human cells per unit area. Primed hMSCs survived better 
in ischemic limbs than control hMSCs. The bars represent mean ± the standard 
error of the mean. The p-value was generated by the Student’s t-test. Please see 
color figure at www.futuremedicine.com/doi/pdf/10.2217/rme.13.17. 
DAPI: 4’,6-diamidino-2-phenylindole; hMSC: Human mesenchymal stem cell; 
HuNu: Human nuclei.
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survival of transplanted cells in ischemic tis-
sue. This could explain why the primed hMSCs 
survived better than controls. In addition, our 
previous study showed that primed hMSCs 
secrete other growth factors, such as insulin-
like growth factor-binding proteins and stem 
cell factor, at higher levels than control hMSCs 
[15]. Thus, these factors may also play an impor-
tant role in increasing cell survival. We have 
previously reported that cell cycle arrest occurs 
in primed hMSCs [15]. Therefore, the increase 
in survival of primed hMSCs in ischemic tissue 
is primarily due to increased cell survival rather 
than increased cell proliferation.
The gene transfer of VEGF or HGF improves 
angiogenesis and limb salvage in patients with 
limb ischemia [25,34,35]. Interestingly, the com-
bination of HGF and VEGF potentiates the 
angiogenic effect through a more robust prolif-
eration and chemotactic response of ECs than 
either growth factor alone [36,37]. A recent study 
demonstrated that the combined VEGF and 
HGF gene therapy leads to a robust angiogenic 
effect in ischemic skeletal muscle [38]. However, 
gene delivery using viral vectors or plasmid 
DNA has safety and low efficacy problems for 
clinical application [39].
Although VEGF is the most important angio-
genic factor promoting therapeutic angiogenesis, 
the clinical application has been compromised 
by the proinflammatory side effects of VEGF 
(e.g., edema due to increased vascular perme-
ability, increased leukocyte adhesion to ECs 
and inflammatory response due to adhesion 
molecule upregulation) [40]. Interestingly, HGF 
has been reported to inhibit the proinflamma-
tory action of VEGF in vitro and in vivo by 
decreasing VEGF-induced leukocyte–endothe-
lial cell interactions and endothelial expres-
sion of adhesion molecules. This suppression 
of VEGF-induced inflammation by HGF is 
mediated by inhibiting the endothelial NF-kB 
pathway [41]. Since the combination of these fac-
tors results in a more robust angiogenic response 
than either growth factor alone without com-
plications of inflammation and edema, it has 
been suggested that “the dynamic duo of VEGF 
and HGF” may be an efficient growth factor 
combination for therapeutic angiogenesis [40]. 
Other proangiogenic factors, such as IL-6 and 
monocyte chemoattractant protein-1 are also 
secreted from hMSCs [42]. This may explain why 
at 14 days after transplantation, control hMSC-
transplanted group showed significant increases 
in the relative ratio of blood perfusion compared 
with the vehicle group (p < 0.05) (Figure 2b).
Sham hMSCs Primed hMSCs
hMSCs Primed hMSCs
Figure 5. Human VEGF and HGF secretion 
from transplanted primed human 
mesenchymal stem cells in ischemic 
hindlimb tissues. (A & B) Representative 
confocal images of (A) hVEGF 
immunofluorescence (green) or (B) hHGF 
immunofluorescence (red) in the sham-, control 
hMSC- and primed hMSC-transplanted ischemic 
hindlimbs 14 days after transplantation. 
Significant expression of hVEGF and hHGF was 
only detected in primed hMSC-transplanted 
ischemic limb tissues, whereas low levels of 
hVEGF and hHGF were observed in the hMSC-
transplanted limb tissues. In each panel, 
expression of hVEGF or hHGF in boxed areas 
appears at higher magnification in the lower 
panels. The nuclei were visualized by DAPI 
staining (blue). Scale bar: 25 µm. Please see 
color figure at www.futuremedicine.com/doi/
pdf/10.2217/rme.13.17. 
DAPI: 4’,6-diamidino-2-phenylindole; 
hHGF: Human HGF; hMSC: Human 
mesenchymal stem cell; hVEGF: Human VEGF.
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The advantage of injecting primed MSCs 
rather than the supernatants of cells is that it 
is possible to have sustained release of para-
crine factors from cells in vivo. We have pre-
viously reported on sustained release of HGF 
and VEGF from primed hMSCs [15]. In short, 
ELISA analyses were conducted after culturing 
primed hMSCs in growth medium for up to 
5 days. The secreted levels of both factors from 
primed hMSCs remained significantly elevated 
compared with control hMSCs even after 
5 days in culture. In this study, immunohisto-
chemical staining for human VEGF and HGF 
demonstrated significant levels of both factors 
in the group transplanted with primed hMSCs; 
whereas there was undetectable to low levels of 
these factors in the sham and mice transplanted 
with nonprimed hMSCs (Figure 5a & 5b). These 
results suggest that primed hMSCs survived 
after transplantation and secreted high levels 
of human VEGF and HGF to enhance angio-
genesis in the ischemic tissues. In addition, we 
could not see any ‘creased’ or partially con-
densed nuclear morphology in anti-human 
nuclei staining, indicating the survival of 
transplanted cells.
In summary, the primed hMSCs used in this 
study may serve as a cellular vector to deliver 
important angiogenic factors to ischemic tissue. 
The factors released from cells are much more 
stable than recombinant peptides, and can 
increase survival of transplanted cells by auto-
crine and paracrine actions to protect residual 
cells in the ischemic area. Our results also indi-
cate that primed hMSCs express other factors 
in addition to VEGF and HGF that promote 
repair and that elevated levels of these factors 
in primed hMSCs contribute to the enhanced 
therapeutic benefit. Furthermore, ensuring 
local trophic support at the ischemic area will 
enhance therapeutic angiogenesis. Our results 
suggest that an autologous cell therapy using 
these primed cells could be a new therapeutic 
strategy to treat ischemic diseases.
Conclusion
We demonstrate that priming hMSCs via the 
methods described in this article enhances 
secretion of critical proangiogenic factors 
resulting in enhanced therapeutic angiogen-
esis in an animal model of hindlimb ischemia. 
Our data recapitulate previous studies show-
ing that hMSC administration restores blood 
flow in a model of hindlimb ischemia but also 
demonstrate that primed hMSCs exhibit signif-
icantly enhanced therapeutic activity compared 
with nonprimed hMSCs in this model. These 
primed cells could be applied to enhance angio-
genic efficacy of stem cell therapy through the 
synergistic actions with critical angiogenic 
factors.
Future perspective
Autologous bone marrow-derived MSCs are 
widely-used cell sources in clinical cell therapy 
for patients with ischemic diseases, among 
others. However, autologous cells have limi-
tations, such as poor functionality or vitality, 
because they are derived from elderly patients. 
Thus, although they are safely applicable to 
real-world practice, the therapeutic efficacy 
would be inherently limited. One way to over-
come such a limited functionality or vitality 
of MSCs from patients is genetic augmenta-
tion or modification. However, considering 
clinical applications, priming of hMSCs with 
cocktails of growth factors would be more fea-
sible and safer than genetic engineering of the 
therapeutic cells.
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